NASDAQ: OTLKOutlook Therapeutics Inc Stock Ownership - Who owns Outlook Therapeutics?
Insider buying vs selling
Have Outlook Therapeutics Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Ghiath M. Sukhtian | Director | 2026-08-12 | 2,525,252 | $0.99 | $2.50MBuy |
| Faisal Ghiath Sukhtian | Director | 2026-07-29 | 95,398 | $1.05 | $99.98kBuy |
| Yezan Munther Haddadin | Director | 2026-06-02 | 29,000 | $0.83 | $24.16kBuy |
| Ghiath M. Sukhtian | Director | 2026-05-28 | 8,539,709 | $0.59 | $5.00MBuy |
| Faisal Ghiath Sukhtian | Director | 2026-05-27 | 122,174 | $0.41 | $49.97kBuy |
| Randy H. Thurman | Director | 2026-05-26 | 5,000 | $0.43 | $2.15kBuy |
| Kurt J. Hilzinger | Director | 2026-05-26 | 400,000 | $0.44 | $176.40kBuy |
| Yezan Munther Haddadin | Director | 2026-05-26 | 34,000 | $0.44 | $14.96kBuy |
OTLK insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when OTLK insiders and whales buy or sell their stock.
OTLK Shareholders
What type of owners hold Outlook Therapeutics Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Ghiath M. Sukhtian | 47.96% | 116,756,592 | $81.26M | Insider |
| Faisal Ghiath Sukhtian | 23.02% | 56,037,758 | $39.00M | Insider |
| Biolexis Pte Ltd | 10.45% | 25,443,159 | $17.71M | Insider |
| Arun Kumar Pillai | 9.44% | 22,982,529 | $16.00M | Insider |
| Pankaj Mohan | 3.40% | 8,285,115 | $5.77M | Insider |
| Syntone Ventures LLC | 0.70% | 1,705,438 | $1.19M | Insider |
| Jeff Evanson | 0.33% | 808,459 | $562.69k | Insider |
| Terry Dagnon | 0.27% | 653,058 | $454.53k | Insider |
| Kurt J. Hilzinger | 0.17% | 423,655 | $294.86k | Insider |
| Scott A. Canute | 0.10% | 246,342 | $171.45k | Insider |
OTLK vs Biotech Stocks
Outlook Therapeutics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.